Kolmar Korea Co., Ltd.

Equities

A161890

KR7161890009

Personal Products

End-of-day quote Korea S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
49,400 KRW -2.18% Intraday chart for Kolmar Korea Co., Ltd. +1.54% -7.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Intercos clarifies its position in lawsuit over Kolmar and Intercos Korea AN
An unknown buyer completed the acquisition of Coway B&H Co., Ltd. from Kolmar Korea Co., Ltd.. CI
Kolmar Korea Narrows Loss in Q4 2023 MT
Kolmar Korea Co., Ltd. completed the acquisition of 45% stake in Yonwoo Co., Ltd. CI
Kolmar Korea Co., Ltd. agreed to acquire 45% stake in Yonwoo Co., Ltd. CI
Kolmar Korea's Net Income Jumps 89.3% in Q2 MT
Kolmar Korea's Net Income Plunges 59.1% in Q1 MT
Kolmar Korea Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kolmar Korea Launches Private Beauty Line in the Middle East MT
Kolmar Korea Co., Ltd. completed the acquisition of 55% stake in Yonwoo Co., Ltd from Ki Joong-hyun and Kim Yeo-ok. CI
Kolmar Korea Co., Ltd. agreed to acquire a 55% stake in Yonwoo Co., Ltd from Ki Joong-hyun and Kim Yeo-ok for approximately KRW 280 billion. CI
Kolmar Korea to Acquire 40% Stake in Biotech Firm Next & Bio MT
Gentrogroup Co., Ltd. announced that it has received KRW 1.999998965 billion in funding from Kolmar Korea Co., Ltd. CI
Gentrogroup Co., Ltd. announced that it expects to receive KRW 1.999998965 billion in funding from Kolmar Korea Co., Ltd. CI
Market Chatter: Kolmar Korea's Net Income Soars Nearly 9% in First Quarter MT
HK inno.N Corporation announced that it has received KRW 49.9999765 billion in funding from Kolmar Korea Co., Ltd. CI
HK inno.N Corporation announced that it expects to receive KRW 49.9999765 billion in funding from Kolmar Korea Co., Ltd. CI
IMM Rose Gold Fund 4 managed by IMM Private Equity, Inc. completed the acquisition of pharmaceutical business unit from Kolmar Korea Co., Ltd.. CI
IMM Rose Gold Fund 4 managed by IMM Private Equity, Inc. agreed to acquire Kolmar Pharma Co., Ltd. and pharmaceutical business unit from Kolmar Korea Co., Ltd. for approximately KRW 300 billion. CI
Kolmar Korea : Korean cosmetics firm in hot water over video praising Japan in trade row RE
Kolmar Korea Co., Ltd. announced that it has received KRW 100.0000785 billion in funding from Kolmar Korea Holdings Co., Ltd. CI
DOW JONES 30 : The Foxconns of fast beauty propel South Korean cosmetics' success in China RE
Kolmar Korea Co., Ltd. announced that it expects to receive KRW 100.0000785 billion in funding from Korea Kolmar Holdings Co., Ltd. CI
CKM Co., Ltd. announced that it has received KRW 660.00031325 billion in funding from Kolmar Korea Co., Ltd. CI
CKM Co., Ltd. announced that it expects to receive KRW 660.00031325 billion in funding from Kolmar Korea Co., Ltd. CI
Chart Kolmar Korea Co., Ltd.
More charts
Kolmar Korea Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of cosmetics. The Company operates its business through three segments. The Cosmetics segment is mainly engaged in the business of original development and design manufacturing (ODM) and original equipment manufacturing (OEM) of cosmetics including skin care, makeup, hair care, body care and others. The Pharmaceutical segment develops and manufactures pharmaceuticals and quasi-drugs including ointment creams, oral solutions, external preparations, and solid preparations. The Food segment is involved in the production and sale of health functional food. The Company is also involved in the rental business. The Company distributes its products in domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
49,400 KRW
Average target price
68,062 KRW
Spread / Average Target
+37.78%
Consensus